Channels - Alzheimer's disease drug development pipeline: 2026 :: FRELIP Discovery

Similar Items: Alzheimer's disease drug development pipeline: 2026

Quick Look
Vascular cognitive impairment and dementia drug‐development pipeline 2025
Quick Look
Interchangeability of CSF and PET to identify Alzheimer's disease pathology
Quick Look
Atrophy signature for alpha‐synuclein copathology in Alzheimer's disease
Quick Look
CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design
Quick Look
Effectiveness of Souvenaid® combined with acetylcholinesterase inhibitors on caregiver burden in Alzheimer´s disease
Quick Look
White matter hyperintensities in Alzheimer's disease in the era of anti‐amyloid therapies
Quick Look
APOE‐associated disease risk and sex‐specific effects in Egyptian Alzheimer's disease: an exploratory study
Quick Look
Promotores program to increase Hispanic/Latino(a) participation in Alzheimer's disease research
Quick Look
Reduced CB1 Cannabinoid Receptor Expression in Alzheimer's Disease and Transgenic Mouse Models
Quick Look
Mid‐ and late‐life depression increases risk of Alzheimer's disease and related dementias in veterans
Quick Look
A fovea‐centered retinal signature linked to plasma biomarkers in prodromal Alzheimer's disease
Quick Look
Perceptions of the use of biomarkers for Alzheimer's disease diagnosis: A systematic review and synthesis of the qualitative literature
Quick Look
Metabolic and renal factors associated with plasma phosphorylated tau analytes used to detect Alzheimer's disease pathology
Quick Look
Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment
Quick Look
Reframing Alzheimer's disease as a complex adaptive system: More than an amyloid beta–tau connection
Quick Look
The multifaceted roles of the transcription factor SP1 in the pathogenesis of Alzheimer's disease: From molecular regulation to therapeutic targets
Quick Look
Physical activity attenuates the association between allostatic load and early Alzheimer's disease‐related biomarkers in older adults
Quick Look
Single‐subject proteomic signatures in Alzheimer's disease reflect clinical phenotypes and distinguish asymptomatic from symptomatic cases
Quick Look
Worth their weight in gray matter? A narrative review of cost‐effectiveness analyses of monoclonal antibodies for Alzheimer's disease
Quick Look
Investigating the amyloid–tau–neurodegeneration framework in Alzheimer's disease using semi‐supervised multimodal imaging data fusion
Quick Look
Association between Alzheimer's/Parkinson's diseases and cancers: Modifying effects of alcohol consumption and viral infections revealed by an ecological study
Quick Look
Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer’s Disease and Mild Cognitive Impairment
Quick Look
Blood DNA methylation signature of cognitive reserve moderates the association between CSF tau pathology and memory in prodromal Alzheimer's disease
Quick Look
Age‐related macular degeneration severity and risk of Alzheimer's disease in older adults in a prospective, community‐based cohort study